216 related articles for article (PubMed ID: 33522704)
21. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
Zhang W; Kuang P; Li H; Wang F; Wang Y
Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
[TBL] [Abstract][Full Text] [Related]
22. Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience.
Crepinsek K; Marinsek G; Kavcic M; Prelog T; Kitanovski L; Jazbec J; Debeljak M
Radiol Oncol; 2021 Dec; 56(1):92-101. PubMed ID: 34957727
[TBL] [Abstract][Full Text] [Related]
23. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
Clappier E; Auclerc MF; Rapion J; Bakkus M; Caye A; Khemiri A; Giroux C; Hernandez L; Kabongo E; Savola S; Leblanc T; Yakouben K; Plat G; Costa V; Ferster A; Girard S; Fenneteau O; Cayuela JM; Sigaux F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Soulier J; Cavé H
Leukemia; 2014 Jan; 28(1):70-7. PubMed ID: 24064621
[TBL] [Abstract][Full Text] [Related]
24. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
[TBL] [Abstract][Full Text] [Related]
25. Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia.
Qazi S; Uckun FM
Haematologica; 2013 Dec; 98(12):e151-2. PubMed ID: 24323986
[No Abstract] [Full Text] [Related]
26. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
[TBL] [Abstract][Full Text] [Related]
27. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
[TBL] [Abstract][Full Text] [Related]
28. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of IKZF1
Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
[TBL] [Abstract][Full Text] [Related]
30. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
31.
Zaliova M; Potuckova E; Hovorkova L; Musilova A; Winkowska L; Fiser K; Stuchly J; Mejstrikova E; Starkova J; Zuna J; Stary J; Trka J
Haematologica; 2019 Jul; 104(7):1407-1416. PubMed ID: 30630977
[No Abstract] [Full Text] [Related]
32. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
[TBL] [Abstract][Full Text] [Related]
34. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
[TBL] [Abstract][Full Text] [Related]
35. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.
Schwab CJ; Chilton L; Morrison H; Jones L; Al-Shehhi H; Erhorn A; Russell LJ; Moorman AV; Harrison CJ
Haematologica; 2013 Jul; 98(7):1081-8. PubMed ID: 23508010
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of IKZF1 deletions and IKZF1
Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
[TBL] [Abstract][Full Text] [Related]
37. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.
Aoe M; Ishida H; Matsubara T; Karakawa S; Kawaguchi H; Fujiwara K; Kanamitsu K; Washio K; Okada K; Shibakura M; Shimada A
Int J Lab Hematol; 2018 Aug; 40(4):427-436. PubMed ID: 29575541
[TBL] [Abstract][Full Text] [Related]
39. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
40. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.
Tokunaga K; Yamaguchi S; Iwanaga E; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2013 Sep; 91(3):201-208. PubMed ID: 23751147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
